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Abstract
Background: Accurate measurement of muscle mass is an important research and clinical tool. High-resolution ultra-
sound (US) has shown potential as a method to assess muscle and fat mass at specific anatomical sites. However, there is
limited evidence for the reliability of US to measure muscle size in patients receiving continuous ambulatory peritoneal
dialysis (CAPD). Therefore, we examined the validity and reliability of an US method compared to a gold standard
comparison for the assessment of a quadriceps muscle in this clinical population.
Methods: Twenty people receiving CAPD (mean age ¼ 56.5 + 16.7 years) at a single dialysis unit were assessed on two
occasions, 7 days apart. Measures of the mid-thigh, such as vastus lateralis (VL) anatomical cross-sectional area (ACSA),
VL muscle thickness and subcutaneous fat thickness were compared for US reliability and validity compared to magnetic
resonance imaging (MRI) measures.
Results: US had high validity against gold standard MRI measures, with intraclass correlation coefficients (ICC) equating
to VL ACSA of 0.95, VL thickness of 0.99 and fat thickness of 0.98. The US measurements also exhibited high intra-rater
reliability (ICCs: VL thickness ¼ 0.98, total muscle thickness ¼ 0.97 and fat thickness ¼ 0.99) in measuring body com-
position at the mid-VL site in the study population.
Conclusions: Valid assessment of regional body composition can be achieved via high-resolution US in patients receiving
CAPD. The validity and reliability of the US in repeated measures (in comparison to the gold standard MRI) warrant
further investigation in the wider chronic kidney disease population.
Keywords
Chronic kidney disease (CKD), magnetic resonance imaging (MRI), reliability, ultrasound (US), validity
Introduction
The prevalence of malnutrition and loss of muscle mass in
stage 5 chronic kidney disease (CKD-5) can be an over-
whelming complication of chronic uraemia.1 Malnutrition
is consistently linked to increased mortality, morbidity and
reduced quality of life in the dialysis population2 with mus-
cle wasting recognised as one of the hallmark characteris-
tics of renal disease.3 Malnutrition and reduced muscle
mass have both been implicated in the functional decline
of chronic kidney disease (CKD) patients2,4 and in the
ageing population.5,6 Patients treated with peritoneal dia-
lysis (PD) are often malnourished, presenting with low
protein levels and decreased fat-free (lean) mass7 but often
with increased overall adiposity (greater visceral fat/sub-
cutaneous fat ratio8). This may be partially attributed to the
glucose-based dialysate used in PD as the increased
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availability of glucose in the dialysate promotes greater
uptake and assimilation by the body,9 thereby potentially
masking the extent of the underlying muscular atrophy.
Anthropometric measures such as skinfold thicknesses
and waist and limb circumferences are routinely taken with
the intention of monitoring the nutritional status of CKD
patients. However, basic measures such as limb circumfer-
ence do not allow accurate composition analysis of the limb
being measured,10 and skinfold measures using calipers are
highly prone to error, regardless of how well trained and
experienced the technician is, as skin calipers have been
shown to overestimate the subcutaneous fat thicknesses of
the thigh in individuals with higher fat values.11
The accurate measurement of muscle mass is an impor-
tant research and clinical tool for assessing change from an
intervention, monitoring progression/deterioration associ-
ated with this stage of CKD or from disuse and frailty-
related ageing.12 Direct measurement of muscle mass is not
always feasible by means of magnetic resonance imaging
(MRI) or other reference methods (e.g. total body potassium,
dual energy x-ray absorptiometry (DEXA)) due to financial
or time costs, general patient access or the sheer volume of
patients that needs to be monitored. However, ultrasound
(US) is a relatively expedient method of this type of data
acquisition and has been shown to safely produce high-
quality images of muscle size and structure.13 Equipment
is inexpensive in comparison to other clinical methods such
as MRI or DEXA and can be taken to the patient at their
bedside, in a research laboratory, or other nonclinical site.
High-resolution US has shown great potential as an
alternative (near-bedside/near-patient) method to assess
muscle and fat mass at specific anatomical sites; it has been
shown to accurately measure change in muscle size result-
ing from anabolic interventions and also to monitor the
effects of ageing and disuse in a variety of healthy and
clinical populations (e.g. healthy adults,14 people with
knee-joint injury,15 people affected by chronic respiratory
disease,16 frail and critically ill patients17,18). However,
there is currently limited evidence for the reliability of
US to measure muscle size in renal populations19–22 and
none in patients receiving PD.
The purpose of this study was, therefore, to examine the
validity and reliability (reproducibility and potential sensi-
tivity) of an US method compared to a gold standard com-
parison (MRI) for the assessment of a quadriceps muscle
(vastus lateralis (VL)) anatomical cross-sectional area
(ACSA), muscle thickness and fat thickness in CKD-5
patients undergoing continuous ambulatory peritoneal dia-
lysis (CAPD) therapy.
Methods
Study design, setting and participants
A cross-sectional design was used for this validity and
reliability study. Twenty (18 male and 2 female) CKD-5
patients undergoing CAPD at a single hospital dialysis unit
volunteered to take part in the study. The CAPD patients
received, during the day, 4  2 L exchanges with a 1.36%
or 3.86% glucose concentration. The dialysis prescription
is based on either 3 1.36%þ 1 3.86% (3:1 regimen) or
2  1.36% þ 2  3.86% (2:2 regimen). The PD fluid
consisted of 5.38 g/l NaCl, 4.48 g/l sodium lactate, 0.184
g/l CaCl2 and 0.051 g/l MgCl2.
Patients were considered eligible if they were 18 years
of age or older, were independently mobile, were fluent in
written and spoken English and were able to give consent.
Patients were excluded if they had any diagnosis of
unstable angina, or amputation that would mean they were
unable to fully participate in the required measurement site.
We limited recruitment to patients on CAPD only to stan-
dardise the type of PD treatment. All participants were
ambulatory and free from recent hospitalisations (i.e. in the
previous month) at the time of assessment.
This research project conformed to the ethical principles
for medical research involving human participants, as set
out by the world medical association declaration of Hel-
sinki, and received ethical approval by the University Hos-
pital of North Staffordshire NHS Trust Ethics Committee.
Participant incentives were not used for this research proj-
ect and all participants provided written informed consent.
Standardisation of assessment procedures
Participants attended two sessions, 7 days apart. US assess-
ments were performed in both sessions at a similar time of
day, and MRI measurements were made during the second
visit only. US and MRI measurements were acquired in a
counter-balanced fashion. All data were acquired with dia-
lysate in the peritoneal cavity. All outcome measures were
taken by a single assessor (blinded to group allocation)
highly experienced in ultrasonography and anthropometry
in both clinical and laboratory settings.
US measurements
All US measurements were attained twice on each occasion
in two-dimensional (2D) brightness mode (B-mode) via a
portable US system (SonoSite® 180 Plus; SonoSite Inc.,
Bothell, Washington, USA) using a 7.5-MHz linear array
probe. Participants lay supine for a period of 20 min prior to
any measurements being taken to allow fluid equilibration
to occur. The probe head was coated with water-soluble
transmission gel which provided acoustic contact without
depressing the dermal surface. Compression of the tissues
was kept to an absolute minimum by maintaining a consis-
tent low pressure with the US probe throughout scanning.
All assessments were undertaken after identification of the
measurement sites by palpitation and then US scanning of
the key anatomical landmarks. The skin surface was
marked with a nonpermanent marker and an angioma
(mole) map was constructed for each participant to ensure
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the correct location and placement of the probe for repeat
assessments.
ACSA of the VL was examined by US at mid-femur
(identified as the distance halfway between the apex of the
greater trochanter and the apex of the lateral epicondyle)
with the US probe held transversely, perpendicular to the
skin, thus allowing a view of the muscle in the axial plane.
The probe was moved in a straight line from the lateral to
the medial edge of the VL over external markers that were
placed on the skin. All scans were captured on videotape to
allow subsequent analysis. The external markers cast an
acoustic shadow on each image which acted as reference
points allowing the ACSA image to be reconstructed on a
computer using imaging software (Adobe Photoshop;
Adobe Systems Inc., San Jose, California, USA). These
reconstructed ACSA images were then measured using
digitising software (NIH Image, National Institute of
Health, Bethesda, Maryland, USA).
US muscle and fat thickness measurements were
recorded in the axial plane at the mid-femur length/mid-
VL width intersect (defined as mid-VL). Once the image
was located, the screen was frozen and the systems calipers
were used to measure tissue thicknesses. Calipers were
removed to capture a second image for later analysis. Fat
thickness was measured as the distance between the skin
surface and the fat/VL interface (or tissue plane). VL mus-
cle thickness was measured as the distance from the fat/VL
tissue plane to the VL/vastus intermedius (VI) tissue plane
(Supplemental Figures 1 and 2). All US measurements
were performed on the left leg and were repeated after 7
days.
MRI measurements
A 0.2-T MRI extremities scanner (E-Scan; ESAOTE Bio-
medica, Genova, Italy) with a flexible coil was used to
obtain axial plane scans at mid-femur length for the left
leg of all participants (Supplemental Figure 3). Axial
plane scans were acquired using a T1-weighted spin echo
profile with the following parameters – time to echo: 16
ms; repetition time: 38 ms and field of view: 160  160
mm2. All participants lay supine for 20 min prior to and
during the scanning procedure. Oil capsules were placed
lightly on the surface of the skin along the mid-femur
length line to highlight this point precisely on the MRI
scan; the oil capsules are clearly visible on T1-weighted
MR images. The capsules were oriented in such a manner
to allow the examiner to identify precisely the mid-VL
point. ACSA of the VL muscle was determined at the
mid-femur length. VL muscle thickness and fat thickness
were obtained at mid-VL (as described above) from the
MRI scans. Images were subsequently analysed using
digitising software (NIH ImageJ).
Statistical analysis
Statistical analyses were performed with SPSS (Version
21.0 for Windows; SPSS Inc., Chicago, Illinois, USA). The
Shapiro–Wilk test was used to check whether data were
normally distributed, and standard statistical methods were
used for the calculation of mean and SDs where appropri-
ate. Validity assessments (US measures and MRI) were
determined by intraclass correlation coefficient (ICC),
Figure 1. Comparison of MRI and US measures of VL ACSA, VL
thickness and fat thickness.The line of equality represents perfect
agreement between the methods (where x ¼ y).
Any data points away from this line demonstrate a bias or level of
disagreement. MRI: magnetic resonance imaging; US: ultrasound;
VL: vastus lateralis; ACSA: anatomical cross-sectional area.
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using a two-way random effects model (absolute agreement
definition23). Bland–Altman analyses with logarithmic
transformations were then performed to compare the two
methods. Intra-observer reliability/repeatability for US
measurement of the VL muscle, muscle thickness and
ACSA was tested through ICC computed by two-way
mixed effects model.24 Typical error (standard error of the
measurement (SEM)) was assessed for both intra-observer
reliability of the US method and as validity between US
and MRI. SEM was calculated using the equation SDdiff/p
2, where SDdiff is the SD of the difference scores between
the two tests. The minimal detectable changes of the US
and MRI methods were defined using a 95% confidence
interval (CI) and the equation (1.96)(
p
2)(SEM).25 Rela-
tionships between measures of muscle mass were assessed
using Pearson’s correlation coefficient. Statistical signifi-
cance was set at p < 0.05, and results are presented as mean
and SD unless otherwise stated.
Results
Participant characteristics
Participants had a mean age of 56.5 + 16.7 years (median¼
60, range: 18–79) with measured height, body mass and
body mass index (BMI) of 170.1 + 7.4 cm, 78.0 + 15.4 kg
and 26.8 + 3.8 kg/m2 (median ¼ 26.3, range: 19.9–38.7),
respectively. The mean CAPD vintage of participants was
30.7+32.2 months with Kt/V¼2.04+0.6, haemoglobin¼
11.6 + 1.4 g/dl, albumin ¼ 37.45 + 4.6 g/dl, venous
tCO2¼ 28.8 + 4.5 (mmol) and parathyroid hormone (PTH)
¼ 22.7 + 23.4 pmol/l, respectively.
Figure 2. VL ACSA, VL thickness and fat thickness log-
transformed Bland–Altman graphs; logaverage along the x-axis, and
logjdifferencej on the y-axis.
Limits of agreement (1.96  SD) are shown with the dashed line,
and mean by the solid line. VL: vastus lateralis; ACSA: anatomical
cross-sectional area.
Figure 3. Intra-rater reliability using US for the measurement of
VL muscle thickness and fat thickness at the mid-VL point.
The line of equality represents perfect agreement between the
measures (where x ¼ y). Any data points away from this line
demonstrate a bias or level of disagreement. US: ultrasound; VL:
vastus lateralis.
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Validity of US measurements
US and MRI were highly and significantly correlated (ICC
for ACSA ¼ 0.95 [95% CI 0.885–0.982], p < 0.001; VL
muscle thickness¼ 0.988 [95% CI 0.970–0.995], p < 0.001
and fat thickness¼ 0.978 [95% CI 0.912–0.994], p < 0.001,
Table 1) with no significant difference between the two
methods (p > 0.2 for all measures). This was initially
graphed with the line of equality between methods to
demonstrate the correlation (Figure 1).
Bland–Altman analyses were then performed of the two
methods being compared (MRI and US) to illustrate the
agreement between them (Supplemental Figure 4). The
sample size was too small to comment on whether accuracy
changes with tissue size, and despite the limits of agree-
ment being quite narrow they may still have been affected
by the one or two outliers. Logarithmic transformations
were performed to remove any skew, and to further inves-
tigate any linearity and correlations. The modulus of the
previously calculated average and difference were used in
the log-transformation, and the new data were plotted (Fig-
ure 2).
The mean (average) differences between US and MRI
for ACSA (0.25 + 0.86 cm2) and VL thickness (0.00 +
0.06 cm) show MRI yielding slightly higher values than US
for each muscle index, with fat thicknesses marginally
lower (0.03 + 0.07 cm). Table 1 summarises the validity
of US measurement of the VL muscle ACSA, muscle thick-
ness and subcutaneous fat compared to MRI measures.
Intra-rater reliability/repeatability of US
The two consecutive sets of US measures (taken 7 days
apart) were highly correlated in the direct measures taken
at the mid-VL site, VL muscle thickness (ICC ¼ 0.981,
[95% CI 0.953–0.992], p < 0.001) and fat thickness (ICC ¼
0.992 [95% CI 0.980–0.997], p < 0.001; Figure 3).
Table 2 summarises the intra-rater reliability of US mea-
sures of the VL muscle thickness, and same site subcuta-
neous fat thickness. Typical error (SEM) was low, with
measures equating to an error of 2.4% (VL thickness, range:
1.8–3.65%) and 10.0% (fat thickness, range: 7.3–15.6%).
Concurrent validity (relationship between measures of
muscle size)
In a further analysis, we explored the relationships between
the different measures of muscle at the mid-VL site (VL
ACSA, total muscle depth and VL-only depth) using US.
VL ACSA was positively correlated with total muscle
thickness (r ¼ 0.530, p ¼ 0.02), VL thickness (r ¼
0.582, p ¼ 0.009) and did not correlate with fat thickness
(r ¼ 0.305, p ¼ 0.204). Total muscle thickness was posi-
tively correlated with VL thickness (r ¼ 0.989, p < 0.001)
and did not correlate with fat thickness (r ¼ 0.267, p ¼
0.229). Finally, VL thickness was not correlated with fat
thickness (r ¼ 0.326, p ¼ 0.138).
Discussion
The results of this study indicate that in comparison with
MRI measurements, the use of 2D B-mode ultrasonography
(US) is a valid means of characterising VL muscle ACSA
in patients receiving CAPD therapy (Table 1). However,
although no statistically significant differences were
revealed between MRI and US assessments of muscle and
subcutaneous fat thickness at the mid-VL site, it is none-
theless evident from the log-transformed data described in
Figure 2 that a small degree of negative systematic bias
exists for both.
Table 1. US validity at mid-VL site compared to MRI.a
N US MRI ICC (95% CI) Absolute difference Typical error (95% CI)
Limits of
agreement
ACSA (cm2) 19 17.82 + 2.82 18.07 + 2.92 0.95 (0.88, 0.98) þ0.25 + 0.86 0.61 (0.46, 0.90) 1.81
VL thickness (cm) 20 1.91 + 0.37 1.91 + 0.36 0.99 (0.97, 0.99) 0.00 + 0.06 0.04 (0.03, 0.06) 0.12
Fat thickness (cm) 10 0.75 + 0.60 0.70 + 0.52 0.98 (0.91, 0.99) 0.03 + 0.07 0.05 (0.04, 0.09) 0.17
ACSA: anatomical cross-sectional area; VL: vastus lateralis; ICC: intra-class correlation; CI: confidence interval; US: ultrasound; MRI: magnetic resonance
imaging.
aResults are presented as mean + SD.
Table 2. Intra-rater reliability of US at mid-VL point.a
N US 1 (cm) US 2 (cm) ICC (95% CI) Typical error (95% CI) MDC (cm)
Mid-VL thickness (cm) 20 1.91 + 0.37 1.92 + 0.35 0.98 (0.95, 0.99) 0.05 (0.04, 0.07) 0.14
Total muscle thickness (cm) 10 1.83 + 0.44 1.83 + 0.42 0.97 (0.94, 0.99) 0.07 (0.05, 0.13) 0.19
Fat thickness (cm) 20 0.95 + 0.83 0.96 + 0.83 0.99 (0.98, 1.00) 0.08 (0.06, 0.11) 0.22
VL: vastus lateralis; US: ultrasound; ICC: intra-class correlation; MDC: minimal detectable change; CI: confidence interval.
aResults are presented as mean + SD.
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The typical error in this study (Table 1) equated to 2.6%
(VL ACSA), 1.8% (VL thickness) and 6.0% (fat thickness).
This is in-line with previous US-MRI validation studies (in
non-renal disease populations) that have used US to mea-
sure the quadriceps muscle (VL ACSA ICC ¼ 0.905, error
¼ 0.38 cm2, healthy participants14; VL ACSA ICC ¼
0.999, healthy participants26; 4.4% error against computed
tomography (CT), coronary arterial disease patients27) and
other sites (hip, ICC ¼ 0.81–0.89, healthy participants28;
lower trapezius, r ¼ 0.77, healthy/asymptomatic partici-
pants29). More importantly, the study results are aligned
with findings from a recent US-MRI validation study which
reported a strong positive correlation between rectus
femoris ACSA and total quadriceps volume (r2 ¼ 0.815,
p < 0.001) in patients with stage 3b–5 CKD.21 In addition,
US-CT validation studies conducted in acute kidney injury,
pre-dialysis CKD and haemodialysis populations have also
found strong correlations between measures of quadriceps
muscle (rectus femoris ACSA, r ¼ 0.826, p < 0.001; rectus
femoris and VI muscle thicknesses, ICC ¼ 0.92–0.97,
p < 0.001) as assessed by these two methods.19,30,31
US scans are able to clearly distinguish between muscle,
fat and connective tissue32 and also allow accurate selec-
tion of measurement sites. This method can provide infor-
mation on ACSA changes along the entire muscle length in
response to training, disuse and sarcopenia.26
Given that clinical disturbances such as fluid accumula-
tion and muscle wasting are very common in CKD, mea-
sures that can distinguish between tissues (unlike BMI,
body mass and limb circumference) and accurately reflect
excess body fat are very useful. The ability to quickly and
accurately assess change in the CKD population may con-
tribute to further explanations and associations with prog-
nosis or mortality, such as ongoing research into the obesity
paradox/reverse epidemiology.33
The US measurements were found to be highly repeatable
(Table 2) in the study participants. Fat measurement error
was greater and more variable (Table 2, repeatability, 10.0%)
than VL muscle thickness using US (Table 2, VL depth
2.4%). The larger variation observed may in part be due to
some compression of the subcutaneous fat beneath the probe
during the procedure, but other studies have also found lower
repeatability in measures of subcutaneous fat where partici-
pants were classed as overweight or obese (ICC¼ 0.9234) as
in this participant group (BMI ¼ 26.8 + 3.8 kg/m2).
The reported ICC of repeated measures of VL muscle
depth (0.98, Table 2) of the thigh is well within, and at the
better end of the range of acceptable-to-excellent reliability
seen in other studies of both healthy and unwell populations
(ICC ¼ 0.72–0.9926,35). Previously, repeated measurements
of ACSA have been reported with ‘good’ reproducibility in
young healthy subjects (ICC¼ 0.87, rectus femoris36); lower
than the accuracy found in the direct depth measurement in
this CKD-5 patient study. The variation in error between VL
muscle measures is small but notable; ACSA measurement
error is marginally higher than measures of VL depth as
there is more scope for the accumulated inflation of small
errors during image collation.
The benefits of using US in cachectic patients to assess
muscle quality and architecture have been previously
alluded to.37 Alongside the demonstrated validity and relia-
bility of this method for CKD patients treated by CAPD,
US is clearly a useful tool for comparative and interven-
tional research studies, especially with the increased expe-
diency of the US method and the reduction in participant
burden (compared to gold standard and other reference
methods), the advantages are even more apparent.
This study also investigated the relationship between the
VL thickness and VL ACSA. Unsurprisingly, VL thick-
ness, total muscle thickness and VL ACSA were highly
correlated with each other, with VL thickness particularly
well correlated to both total muscle thickness and VL
ACSA (p < 0.01).
Using a thickness measure as an alternative to ACSA
has been explored in other studies and found to provide
very similar degrees of correlation (and therefore informa-
tion) with slightly better concordance in the lower extremi-
ties such as the upper thigh (r ¼ 0.922–0.949, p < 0.00138)
or mid-quadriceps (r ¼ 0.9139), compared to the upper
extremities (mid-upper arm, r¼ 0.870–0.915, p < 0.00140).
This highly significant correlation between these mea-
sures means a direct thickness measure might be able to
provide acceptably similar information for monitoring and
assessment purposes as the ACSA would. It is a more
expedient process and measure in comparison to the more
time-intensive image reconstruction and measurement of
ACSA. By using one clear image at a single site, research-
ers and/or clinicians can minimise the risk of both measure-
ment and processing errors.
Some limitations of our investigation should be acknowl-
edged. Measuring the muscle and subcutaneous fat at the
mid-VL site only means the validity and reliability of US
cannot necessarily be applied to all body sites. Similarly, a
direct comparison of our findings with those of others in
similar clinical settings is not possible. In addition, this study
used only a single assessor when examining reliability, and
thus the results are for intra-rater reliability alone. Previous
research has shown excellent inter-rater reliability in patients
with acute kidney injury.22 However, we cannot make any
conclusive statement as to whether another assessor would
show a similar level of accuracy in their measures. US
assessments are generally performed by practitioners with
specific training and experience to avoid common measure-
ment issues such as excessive compression of tissues and
misplacement of the US probe. Therefore, generalisation for
use by a multitude of clinicians is not possible without fur-
ther inter-rater reliability testing or training.
Conclusions
Valid assessment of regional body composition can be
achieved via high-resolution US in CKD-5 patients
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receiving CAPD. In the study population, there was a high
correlation between VL ACSA and VL muscle thickness in
the axial plane, with all US measures highly repeatable and
characterised by low measurement error. The validity and
reliability of the US in repeated measures (in comparison to
the gold standard MRI) warrant further investigation in the
wider CKD patient population. Future studies aiming to
investigate the clinical utility of US should also explore the
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